Adverse Events Associated With Novel Cancer Therapies

Advancements in novel anticancer therapeutics have enhanced the precision with which cancerous cells can be selectively identified and destroyed. Breakthroughs in adoptive cell therapy, checkpoint inhibitors, and anti-drug conjugates have been at the forefront of these advancements. The purpose of this review is to highlight the mechanisms of action underlying these novel anticancer therapeutics, provide an overview of their reported ocular adverse effects (AE), and where possible, provide a starting point for ocular AE prophylaxis and management.